Tampilkan postingan dengan label NHSN. Tampilkan semua postingan
Tampilkan postingan dengan label NHSN. Tampilkan semua postingan

Rabu, 10 Agustus 2011

Central line + positive blood culture = CLABSI (not!)

There's a thoughtful commentary in a recent issue of Clinical Infectious Diseases by Tom Fraser and Steve Gordon at Cleveland Clinic on problems related to CDC's central line associated bloodstream infection (CLABSI) case definition. We've blogged about this before. The definition is old and was designed to maximize sensitivity long before anyone thought about public reporting. But the issues of poor specificity of this definition are haunting many of us, particularly those who work at hospitals with cancer centers. Unfortunately, neutropenic cancer patients not uncommonly have translocation of enteric flora across their intestinal mucosa and the resulting bloodstream infection in the presence of a central line forces us to label these as CLABSIs, even though these infections are not at all related to the central line. Ten years ago no one cared about this surveillance technicality. Now, in the era of public reporting this is a big problem. In fact, nearly every "CLABSI" in the medical ICU of my hospital falls into this category. Fraser and Gordon show us how this is handled at their hospital with a modification to the CDC definition that is used for internal purposes. Hopefully relief is on the way. CDC is very interested in this issue and has assembled a committee that is actively evaluating the issue.

Minggu, 12 Desember 2010

Mandatory reporting of HAIs: A work in progress

The December issue of American Journal of Infection Control, has a paper looking at validation of central line associated bloodstream infection (CLABSI) reporting in Connecticut, where all 30 acute care hospitals are required to report CLABSIs from 1 ICU via the National Healthcare Safety Network (NHSN). All positive blood cultures for the fourth quarter of 2008 for these ICUs were reviewed by a trained nurse microbiologist (the gold standard for the study) and compared to locally collected data. A total of 770 blood cultures were reviewed and the validator detected 48 CLABSI cases.

The validity parameters were as follows:

  • Sensitivity  48%
  • Specificity  99%
  • Positive predictive value 85%
  • Negative predictive value  94%
So, as you might suspect even before seeing these data, the major problem with mandatory reporting programs is a failure to adequately detect cases. Keep that in mind when you read through Consumer Reports honor roll of US hospitals that reported no CLABSIs! While I continue to believe that mandatory reporting is the right thing to do, much work is still needed to produce valid data.

Senin, 08 November 2010

1st Annual Illinois Conference on HAI: The SSI rates don't exist anymore edition


I ate all of the Illinois-shaped
chocolates. Sorry!
I had the pleasure of attending and speaking at the Illinois APIC conference this past Friday in Springfield, Illinois.  Lincoln was everywhere for some reason; I was expecting Homer or Bart statues...

The first speaker was Kathy Allen-Bridson, RN BSN CIC who is a Nurse Consultant at CDC's NHSN.  She gave an excellent talk describing how to apply NHSN definitions. She, Marc Wright (one of the conference organizers), Joan Hebden, Gloria Morrell and Teresa Horan have published a series of cases studies that aid IPs in the application of NHSN definitions of HAIs.  The first three of these have appeared in the June, September and October issues of APIC. (scroll down to the Special Article section)  I do think that these should be free to everyone and not require a membership or subscription, especially given the large role that CDC had in creating these vignettes.

As far as CLABSI definitions, there was some interesting discussion around Criterion 2 that requires the "same" skin contaminant from >2 blood cultures drawn <2 days apart. For the definition of same, NHSN suggests
that organisms are the same if they have the same antimicrobial sensitivities or only differ in susceptibility to ONE antibiotic.  Thus if they differ by 2 or more antibiotic susceptibilities then they are different and the BSI is not a CLABSI.  The interesting discussion came up around what to do with susceptibilities tested by the microbiology lab, but not reported.  Since some/many labs only report susceptibilities to clinicians for antibiotics on formulary or unrestricted antibiotics, should IPs go to the lab and search for susceptibility mismatch on antibiotics tested in the lab but not reported?  A show of hands suggested that 50% do the extra search and 50% don't.  This is something NHSN might want to address.

The second speaker was Maggie Dudeck MPH CPH, who is also with CDC's NHSN. She gave a really thorough talk on how to use NHSN for analysis and generate reports.  I found this very useful.  Additionally, she discussed that NHSN will no longer report SSI rates!  As of now, NHSN will only report SSI Standardized Infection Ratios (SIRs). You can read more about SSI SIRs here in the NSHN special edition newsletter.  Basically, SIRs are estimated by dividing reported SSI rates by expected infection rates estimated using a "to be published" logistic regression formula.  Thus, SIR>1 will suggest SSIs greater than expected and SIR<1 will suggest SSIs lower than expected.  This is pretty interesting, although as a patient and clinician, I would still want to see that actual rates. (FYI in CLABSI they will report rates and SIR, which I think is better)  In addition, if new information becomes available that might improve the SIR calculation, it is not clear how quickly that will be incorporated, if at all.

Overall, it was a great conference. I had a lot of fun speaking about "Reducing CLABSIs through Blood, Sweat and Tears, With a Happy Ending", interacting with the 200 or so IPs in attendance and eating all of the Illinois-shaped chocolates.  It was also fun to be recognized by a few people who read this blog. Thanks for saying hello!

Minggu, 26 September 2010

My new VAP definition is unstoppable!

As we have blogged on numerous occasions, existing ventilator-associated pneumonia (VAP) definitions (for both clinical and surveillance purposes) are craptastic. In Mike’s recent post about this problem, he calls for CDC to collaborate with IPs and hospital epidemiologists to help develop better definitions. Well, the CDC is doing just that. They have been working with critical care and ID physicians, as well as with some of the CDC Epicenters, to develop and assess a new definition for “VALORI” (Ventilator Associated Lower Respiratory Infection). A simple algorithmic summary of the approach is below, courtesy of Dr. Shelley Magill, who gave an excellent talk at a recent CDC/HHS meeting I attended in DC:


The major objection voiced to the draft VALORI definition is that by removing some aspects that introduce subjectivity, the definition becomes more of a severity of illness measure than a description of what we know clinically to be VAP. The definition also retains some elements that are subjective (or hinge on clinician behavior, such as use of antibiotics), so it isn’t clear if it will have better performance characteristics than the current NHSN definitions.

In my view, we should not use VAP as a quality measure, period. VAP rates should not be compared across hospitals, publicly disclosed, or used in any pay-for-performance schemes. For as soon as they are, hospitals will quickly learn to reduce their rates without doing anything that actually improves patient outcomes (e.g. by narrowly interpreting clinical signs or CXR findings, by seeking consensus among multiple IPs for each case, or by incorporating clinician’s opinions regarding the diagnosis).

In the meantime, we can probably agree on some practices that could be selected for public reporting and benchmarking (i.e. process measures). The practices chosen should be those that are demonstrated to improve meaningful patient outcomes in controlled clinical trials. A great example is this 4-center study of spontaneous awakening + spontaneous breathing trials. The investigators, recognizing the futility of defining VAP, instead demonstrated reductions in ICU days, vent days, hospital days, and mortality in the intervention group.

Kamis, 27 Mei 2010

17 states report CLABSI rates. Why only 17?

The CDC just released the First State-Specific Healthcare-Associated Infections Summary Data Report, which focuses on CLABSI. HHS press release is available here. Needless to say, we are all disappointed with the rates here in Maryland given how hard the State and hospitals have worked at preventing these infections. No one seems more disappointed than Peter Pronovost. No excuses.

Senin, 26 April 2010

NHSN Definitions for CLABSI: Preventing the Unpreventable?

There is a nice Concise Communication in the May issue of ICHE out of the University of Michigan (Go Blue). The investigators were interested in the specificity of NHSN CLABSI definitions in their Critical Care Medicine Unit (CCMU) and their SICU during the period after implementation of CLABSI bundles. They excluded from review BSIs that were determined to be central line-related BSIs (CLRBSI) since they required positive cath-tip cultures or differential time to positivity. They then had all CLABSIs, as determined by unit-designated infection preventionists using NHSN definitions, reviewed further by two non-blinded ID physicians.

To cut to the chase, since this post shouldn't be longer than the original concise communication, there were 30 non-secondary BSIs in the CCMU, 10 were CLRBSI and 20 were CLABSI. Of the 20 CLABSI, 9 (45%) were considered to have central line sources, 9 were considered contaminated blood cultures and 2 were considered transient post-op BSIs. Of the 8 non-secondary BSIs in the SICU, there were no CLRBSI and 5 (63%) were intra-abdominal sources and 1 unknown non central-line source leaving 2 confirmed CLABSI. Thus, of the original 38 IP-reported CLABSIs in the two ICUs, ID physicians confirmed 21, leaving them with an positive predictive value of 55%; close to flipping a coin.

Now, I didn't read the discussion section of the paper (who has the time!), however, since they only looked at IP determined CLABSIs they can't report sensitivity or specificity; in fact they didn't calculate the PPV, I did that. Given that so many CLABSIs appeared to be contaminated blood cultures, efforts could now be directed to preventing those, but the clinical benefit to the patient would likely be small apart from a few avoiding unnecessary antibiotic exposure. Efforts spent limiting those non-BSI CLABSIs, I suspect will be undertaken since we all have to get to zero. It's just sad that those efforts won't help our patients.

Selasa, 30 Maret 2010

VAP: Do you know it when you see it? (Again!)

There's a new paper on the utility (or lack thereof) of CDC's definition of ventilator-associated pneumonia. In this study 4 persons reviewed 50 cases of ventilated patients with respiratory deterioration >48 hours after intubation. Two reviewers were experienced infection preventionists who applied the CDC definition. A third IP used a modification of the CDC definition that was more quantitative, and the fourth reviewer was a physician board-certified in infectious diseases and critical care who used clinical judgment to define VAP. Using the standard definition, one IP assigned the VAP diagnosis to 11 patients and the other, 20 patients. The IP using the modified definition assigned 15 cases as VAP. The physician diagnosed VAP in 7 patients. The IPs agreed on 62% of cases (kappa=0.40). All 4 reviewers agreed on the VAP diagnosis in only 4 cases. This is not the first study to show how complex assigning the diagnosis of VAP can be.

Given that public reporting has raised the stakes to high levels, the CDC can no longer ignore this issue. Consumers cannot make choices on where to receive care if inter-hospital comparisons of infection rates are not valid. There needs to be a convening of IPs and hospital epidemiologists who use the definitions on a daily basis to thoroughly assess each of the HAI case definitions and begin to work on the development of new ones that will be fair to hospitals and helpful to consumers. Otherwise, it's garbage in, garbage out, and the entire concept of public reporting is undermined.

Selasa, 23 Maret 2010

Defining our way to zero?

Here is a quote from an Emerging Infections Network post today, regarding how we define central-line associated bloodstream infections (CLABSI):

Is it really worthwhile to adjudicate blood stream infections in patients with central lines as "primary" or "secondary"? The adjudication according to the "definition" is still subjective. For example, a Klebsiella bacteremia in a pt with a PICC and PEG was ascribed to "gastroenteritis" since the pt had some coincident diarrhea and stool fecal leukocyte+ (hence bacteremia was considered secondary). A candidemia was attributed to pneumonia since the pt was immunocompromised (on steroids for BOOP), had a fluctuating CXR and had Candida in his sputum (hence the candidemia was considered secondary). I was told that these attributions were completely reasonable since they were compatible with the definitions and that the institution regularly passes muster when audited. It is distasteful to argue but anyone looking closely would see a discrepancy between the clinical diagnosis and the adjudicated diagnosis. Since the public is taking these numbers seriously, there is a problem.
This EIN post goes to the heart of a very important issue in healthcare associated infection reporting—the subjective interpretation of National Healthcare Safety Network (NHSN) definitions. Of course we already know that ventilator associated pneumonia (VAP) rates are a load of crap (I’ll leave it to Klompas and Platt to explain why). It is less well recognized how much fiddling is going on with the CLABSI definition. The post above is a great example of what is happening across the country in hospitals that are under increasing pressure to “get to zero”, and as public reporting of infection rates becomes the norm rather than the exception. Hence those hospitals that apply the NHSN CLABSI definition very strictly are punished with higher CLABSI rates. Meanwhile, hospitals celebrating “zero” rates may in fact be no more “safe” than before they began fudging their definitions.

How to fix this? Either via an expensive and cumbersome validation system for public reporting (any ideas for CDC and state public health departments on how to do this?), or via more specific definitions from NHSN.